Skip to main content
. 2024 May 5;12(5):500. doi: 10.3390/vaccines12050500

Figure A13.

Figure A13

Vaccine efficacy (VE) for respiratory syncytial virus (RSV) vaccines in older adults (age ≥ 70/75 years) with lower respiratory tract disease (LRTD) with 3 or more signs/symptoms (I2 0.0%, 95% CI 0.0 to 84.7; tau2 0.0, 95% CI 0.0 to 2.732; Q = 0.71, p = 0.871) [51,52,81].